Multiply Labs raises $75M to optimize pharmaceutical manufacturing with robots
What happened
Multiply Labs, a startup focused on automating pharmaceutical manufacturing, secured $75 million in Series B funding. The round was led by medical researcher Patrick Soon-Shiong and included investors such as AstraZeneca and Teradyne, a robotics firm. Multiply Labs develops robotic equipment designed to streamline drug production workflows.
Why it matters
Pharmaceutical manufacturing traditionally relies on manual processes that can slow production and introduce quality risks. Multiply Labs’ automation approach targets these inefficiencies by integrating robotic technology directly into drugmaking operations. This can lower costs, speed up production timelines, and reduce human error. For drugmakers, upgrading manufacturing with robots represents a push to meet growing demand more reliably while managing tighter regulatory and cost pressures.
The involvement of established firms like AstraZeneca signals confidence that robotic automation is poised to shift pharma supply chains. Teradyne’s participation also suggests the robotics hardware component will scale alongside the software controls to help pharma plants become more automated factories. Funding at this scale means Multiply Labs has the resources to accelerate product development and expand its reach.
What to watch next
The next phase to track will be how quickly Multiply Labs can deploy its robotic systems in commercial manufacturing settings and demonstrate measurable gains in speed, cost, and quality. Increased adoption by major pharmaceutical companies could pressure legacy contract manufacturers to modernize or risk losing business. Keep an eye on announcements around partnerships with drugmakers or regulatory clearances validating automated production processes. The overall trend toward automation in pharma manufacturing will shape supply security, cost competitiveness, and innovation timelines.
AI Quick Briefs Editorial Desk